NCT03758716View on ClinicalTrials.gov

An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 3, 2017

Primary Completion Date

January 28, 2019

Study Completion Date

September 19, 2019

Conditions
Atopic Dermatitis
Interventions
DRUG

FB825, FB825-15D11, Anti-CemX

Pharmaceutical form: 20mg/ml solution Route of administration: IV

Trial Locations (1)

Unknown

National Taiwan University Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Fountain Biopharma Inc.

INDUSTRY

NCT03758716 - An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis | Biotech Hunter | Biotech Hunter